Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;4(2):305-13.
doi: 10.2147/vhrm.s1154.

New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications

Affiliations
Review

New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications

Conor J McCann et al. Vasc Health Risk Manag. 2008.

Abstract

New data have re-established the importance of anticoagulation of patients with ST segment elevation myocardial infarction (STEMI), both as an adjuvant to reperfusion therapy or in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be superior to conventional unfractionated heparin. This article summarizes current understanding of the underlying pathophysiology of STEMI and provides a comprehensive review of emerging trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin inhibitors in this setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interaction of anti-thrombotic agents with coagulation cascade. UFH-antithrombin III complex has approximately equal inhibitory effects on factor Xa and IIa. LMWH-antithrombin III complex has greater relative specificity for factor Xa. Pentasaccharide-antithrombin III complex acts only on factor Xa. Abbreviations: UFH, unfractionated heparin; LMWH, low molecular weight heparin; DTI, direct thrombin inhibitors.

References

    1. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine. 2006;354:1477–88. - PubMed
    1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation. 2004;110:588–636. - PubMed
    1. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002;105:1642–9. - PubMed
    1. Antman EM. The search for replacements for unfractionated heparin. Circulation. 2001;103:2310–14. - PubMed
    1. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999;99:2720–32. - PubMed

MeSH terms